- Why are vegetarians more likely to suffer from depression than meat eaters?
- Small wireless device implanted between skin and skull helps kill cancer cells
- Will the mRNA vaccine that can cure cancer come out near soon?
- Allogeneic T-cell therapy set for landmark first approval
- Boston University denies that the new COVID strain they made has 80% fatality rate
- A new generation of virus-free CAR-T cell therapy
The 4th inactivated COVID-19 vaccine launched in China now
The 4th inactivated COVID-19 vaccine launched in China now. On June 1, the inactivated COVID-19 vaccine (Vero cell) developed by China Kangtai Biological Products Co., Ltd. was officially vaccinated for local residents in Guangdong Province, China.
This is China’s fourth inactivated vaccine and requires 2 doses. The first batch of Kangtai Covid-19 vaccine supplied to Shenzhen residents was 520,000 and was distributed to 320 vaccination points in Shenzhen on June 1, 2021.
China’s inactivated vaccines are already a very mature technical route: mature R&D platforms, stable production processes, controllable quality standards, good protection effects, easy to scale production, and have internationally accepted safety and effectiveness evaluation standards. Moreover, inactivated vaccines can increase human antibodies and reduce the chance of infection with the new coronavirus. It is suitable for the elderly or children, and people with weakened immune systems and weak physiques.
Kangtai Biologics COVID-19 inactivated vaccine schedule:
- February 2020, Kangtai Biotechnology started vaccine research and development.
- September 2020, obtained clinical trial approval from the State Drug Administration.
- April 2021, good news came: the expected protection rate exceeded 90%!
- June 1, 2021, the inoculation ceremony of Kangtai Bio-New Coronavirus Inactivated Vaccine (KovicTM) was held in Shenzhen Bay Sports Center.
Q&A about Kangtai Biological COVID-19 Inactivated Vaccine
1. Is the newly launched Kangtai Covid-19 vaccine safe?
The Phase I/II clinical trial data of this new inactivated coronavirus vaccine (KovicTM) were published on the Medrxiv platform jointly operated by Yale University, Cold Spring Harbor Laboratory, and the British Medical Journal and the English version of the Chinese Medical Journal. The data shows that the vaccine has an expected protection rate of over 90% and no serious adverse reactions above grade 3 occurred. The overall adverse reaction rate is not significantly different from that of the placebo group. It has excellent effectiveness and safety.
2. Can it be mixed with other vaccines?
A: Specific analysis of specific circumstances:
① Regarding the selection of new coronavirus vaccines, experts said that it is not recommended to use vaccines of different technical routes to be mixed, and vaccines of the same technical route can be mixed when there is a stall.
②Shao Yiming, a researcher at the China Centers for Disease Control and Prevention, consultant to the WHO Vaccine R&D Committee: We say that all vaccinations are completed, that is to say, the completion of an immunization program is the completion of all the required vaccinations. Two or three injections, our current instructions recommend using the same vaccine to complete all injections. When the supply of vaccines is out of stock, we can use the same technical route, such as inactivated vaccines, different manufacturers Produced can also be mixed.
③Wang Huaqing, chief expert of the China Centers for Disease Control and Prevention’s immunization program, also added, “If I finish the first dose in a certain place, but I go to work and live in another place, the vaccine is not provided locally. We can substitute products of the same technical route, but inactivated vaccines can only replace inactivated vaccines, and protein subunit vaccines can only replace protein subunit vaccines.”
④ “New Coronavirus Vaccination Technical Guidelines (First Edition)” clearly pointed out that at this stage, it is recommended to use the same vaccine product to complete the vaccination. In case of special circumstances such as the inability to continue the supply of vaccines, the recipients are vaccinated in different places, and the same vaccine product cannot be used to complete the vaccination, the same type of vaccine products of other manufacturers can be used to complete the vaccination.
In other words, the first dose is an inactivated vaccine, and the second dose is recommended to use inactivated vaccines from the same manufacturer, or inactivated vaccines produced by other companies can also be used.
3. Can residents outside of Guangdong Province of China be vaccinated?
A: The first batch of vaccines is currently only supplied to Guangdong Province.
4. Can the elderly and children be vaccninated?
A: As long as the elderly over 60 years of age are in good health, they can be vaccinated according to the local vaccination strategy. At present, people under the age of 18 have not been included in the scope of the vaccination population.
Previous news about the cooperation between AstraZeneca and Kangtia Bio
Kangtai Bio/AstraZeneca: Adenovirus vector COVID-19 vaccine AZD1222
On August 6, 2020, AstraZeneca announced that it had signed an exclusive authorization cooperation framework agreement with Kangtai Biologics in the Chinese mainland market to actively promote the research and development of the adenovirus vector vaccine AZD1222 in the Chinese mainland market through technology transfer. Production, supply and commercialization. In the future, the two parties will continue to explore the possibility of cooperation with the vaccine in other regions and markets.
On November 23, 2020, AstraZeneca announced that the Phase III clinical interim analysis of AZD1222 has reached the primary efficacy endpoint. Based on the data of 332 symptomatic COVID-19 patients accumulated in 17,177 subjects, one dose of the vaccine can produce 76% of the protective effect, and the interval between two vaccination is more than 12 weeks, the protective effect of the vaccine reaches 82% . In terms of protection against severe COVID-19, the effectiveness of two doses of the vaccine is 100%. Previously, the British regulatory agency had granted emergency use authorization for the vaccine and recommended that the interval between two vaccinations be 4-12 weeks.
(source:internet, reference only)